Differential (Click to cross reference) advances in neurology adverse drug reaction alemtuzumab B cell lymphocytes carcinoma carcinoma of breast central nervous system, infection of complications efficacy fingolimod fumarate herpes virus infection iatrogenic neurologic disorders immunomodulation infection interferon beta 1-a laquinimod meningitis meningitis, aseptic meningitis, iatrogenic monoclonal antibodies MRI, abnormal multiple sclerosis multiple sclerosis, chronic progressive multiple sclerosis, prophylaxsis multiple sclerosis, relapsing multiple sclerosis, treatment of ocrelizumab placebo prevention of neurologic disorders progressive multifocal leucoencephalopathy review article safety treatment of neurologic disorder viral infection viral infection, CNS viral infection, reactivation

Showing articles 0 to 6 of 6 Progressive Multifocal Leukoencephalopathy in a Patient with Progressive Multiple Sclerosis Treated With Ocrelizumab Monotherapy JAMA Neurol 78:736-740, Patel,A.,et al, 2021 Two Cases of Meningitis Associated with Ocrelizumab Therapy Mult Scler Rel Dis 38:101866, Theriault, M. & Solomon, A.J., 2020 Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis NEJM 376:221-234,280, Hauser, S.L.,et al, 2017 Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis NEJM 376:209-220,280, Montalban, X.,et al, 2017 Newer Agents in the Treatment of Multiple Sclerosis Neurologist 19:104-117, Pawate, S. & Bagnato F., 2015 Multiple Sclerosis-Quenching the Flames of Inflammation Lancet 378:1759-1760, , 2011 Showing articles 0 to 6 of 6